BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18711102)

  • 21. Sunitinib-induced hand-foot syndrome: a new, distinct form.
    Fife DJ; Wu JJ; Behnam SE; Linden KG
    Clin Exp Dermatol; 2010 Mar; 35(2):200-1. PubMed ID: 19486049
    [No Abstract]   [Full Text] [Related]  

  • 22. Acute cardiac failure after sunitinib.
    Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
    Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
    [No Abstract]   [Full Text] [Related]  

  • 23. Hand-foot and stump syndrome to sorafenib.
    Lai SE; Kuzel T; Lacouture ME
    J Clin Oncol; 2007 Jan; 25(3):341-3. PubMed ID: 17235051
    [No Abstract]   [Full Text] [Related]  

  • 24. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis.
    Suwattee P; Chow S; Berg BC; Warshaw EM
    Arch Dermatol; 2008 Jan; 144(1):123-5. PubMed ID: 18209189
    [No Abstract]   [Full Text] [Related]  

  • 25. Reversible posterior leukoencephalopathy syndrome induced by sunitinib.
    Martín G; Bellido L; Cruz JJ
    J Clin Oncol; 2007 Aug; 25(23):3559. PubMed ID: 17687168
    [No Abstract]   [Full Text] [Related]  

  • 26. Rectal perforation after two years of treatment with sunitinib for metastatic kidney cancer.
    Bladé JS; Bourgouin S; Romeo É; Boudin L; de Jauréguiberry JP
    Presse Med; 2014 Nov; 43(11):1293-5. PubMed ID: 24999082
    [No Abstract]   [Full Text] [Related]  

  • 27. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
    Ruggeri EM; Cecere FL; Moscetti L; Doni L; Padalino D; Di Costanzo F
    Ann Oncol; 2010 Sep; 21(9):1926-1927. PubMed ID: 20729535
    [No Abstract]   [Full Text] [Related]  

  • 28. Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.
    Yıldız I; Varol U; Şen F; Kılıç L
    Anadolu Kardiyol Derg; 2014 Nov; 14(7):654-6. PubMed ID: 25163084
    [No Abstract]   [Full Text] [Related]  

  • 29. Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib.
    Bamias A; Lainakis G; Manios E; Koroboki E; Gyftaki R; Zakopoulos N; Dimopoulos MA
    J Chemother; 2009 Jun; 21(3):347-50. PubMed ID: 19567357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
    J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
    [No Abstract]   [Full Text] [Related]  

  • 31. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Garfield DH; Hercbergs A; Davis PJ
    J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
    [No Abstract]   [Full Text] [Related]  

  • 32. Cardiotoxicity associated with sunitinib.
    Hariharan S; Lowry S
    Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
    [No Abstract]   [Full Text] [Related]  

  • 33. Blackberry-induced hand-foot skin reaction to sunitinib.
    Boone SL; Jameson G; Von Hoff D; Lacouture ME
    Invest New Drugs; 2009 Aug; 27(4):389-90. PubMed ID: 18998055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
    Kalantari HR
    Br J Cancer; 2009 Oct; 101(7):1222-3; author reply 1224. PubMed ID: 19755985
    [No Abstract]   [Full Text] [Related]  

  • 35. How does sunitinib cause hypothyroidism?
    Hershman JM; Liwanpo L
    Thyroid; 2010 Mar; 20(3):243-4. PubMed ID: 20187779
    [No Abstract]   [Full Text] [Related]  

  • 36. [Sunitinib-induced pyoderma gangrenosum].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Dec; 140(12):841-2. PubMed ID: 24315238
    [No Abstract]   [Full Text] [Related]  

  • 37. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New drugs; sunitinib and sorafenib].
    van Bronswijk H; Dubois EA; Osanto S; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2888-90. PubMed ID: 18257434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.
    van der Veldt AA; van den Eertwegh AJ; Hoekman K; Barkhof F; Boven E
    Ann Oncol; 2007 Oct; 18(10):1747-50. PubMed ID: 17890217
    [No Abstract]   [Full Text] [Related]  

  • 40. Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy.
    Padhy BM; Shanmugam SP; Gupta YK; Goyal A
    Br J Clin Pharmacol; 2011 May; 71(5):777-9. PubMed ID: 21480952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.